Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Grimwade

Showing results (21-30 of 104) with videos related to

Pageof 11
Sort By:
Blood Reviews|November 17, 2010
Independent prognostic variables in acute myeloid leukaemiaMatthew L Smith, Robert K Hills, David Grimwade
British Journal of Haematology|November 5, 2011
The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemiaKaren A Breen, David Grimwade, Beverley J Hunt
British Journal of Haematology|April 2, 2005
Biology and management of relapsed acute myeloid leukaemiaCharles Craddock, Sudhir Tauro, Paul Moss, et al.
Blood|December 15, 2015
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevanceDavid Grimwade, Adam Ivey, Brian J P Huntly
Best Practice & Research. Clinical Haematology|June 8, 2014
Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?David Grimwade, Jelena V Jovanovic, Robert K Hills
Haematologica|September 5, 2007
Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disordersAndreas Reiter, David Grimwade, Nicholas C P Cross
Seminars in Oncology|August 12, 2008
Development of minimal residual disease-directed therapy in acute myeloid leukemiaSylvie D Freeman, Jelena V Jovanovic, David Grimwade
Cancer Treatment and Research|March 23, 2010
Acute promyelocytic leukemia: a paradigm for differentiation therapyDavid Grimwade, Anita R Mistry, Ellen Solomon, et al.
Blood Reviews|March 19, 2003
The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the diseaseAnita R Mistry, Eva W Pedersen, Ellen Solomon, et al.
International Journal of Hematology|July 26, 2013
Acute myeloid leukaemia with mutated NPM1 presenting with extensive bone marrow necrosis and Charcot-Leyden crystalsGordon Taylor, Adam Ivey, Benedict Milner, et al.
Pageof 11

Showing results (21-30 of 104) with videos related to

Sort By:
Pageof 11
Blood Reviews|November 17, 2010
Independent prognostic variables in acute myeloid leukaemiaMatthew L Smith, Robert K Hills, David Grimwade
British Journal of Haematology|November 5, 2011
The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemiaKaren A Breen, David Grimwade, Beverley J Hunt
British Journal of Haematology|April 2, 2005
Biology and management of relapsed acute myeloid leukaemiaCharles Craddock, Sudhir Tauro, Paul Moss, et al.
Blood|December 15, 2015
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevanceDavid Grimwade, Adam Ivey, Brian J P Huntly
Best Practice & Research. Clinical Haematology|June 8, 2014
Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?David Grimwade, Jelena V Jovanovic, Robert K Hills
Haematologica|September 5, 2007
Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disordersAndreas Reiter, David Grimwade, Nicholas C P Cross
Seminars in Oncology|August 12, 2008
Development of minimal residual disease-directed therapy in acute myeloid leukemiaSylvie D Freeman, Jelena V Jovanovic, David Grimwade
Cancer Treatment and Research|March 23, 2010
Acute promyelocytic leukemia: a paradigm for differentiation therapyDavid Grimwade, Anita R Mistry, Ellen Solomon, et al.
Blood Reviews|March 19, 2003
The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the diseaseAnita R Mistry, Eva W Pedersen, Ellen Solomon, et al.
International Journal of Hematology|July 26, 2013
Acute myeloid leukaemia with mutated NPM1 presenting with extensive bone marrow necrosis and Charcot-Leyden crystalsGordon Taylor, Adam Ivey, Benedict Milner, et al.
Pageof 11